Key result
Ivabradine improves cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients with heart rates ≥ 70 bpm and in patients with stable angina.
Why the study?
Does ivabradine improve cardiac outcomes in patients with coronary artery disease and chronic heart failure?
Does ivabradine improve cardiac outcomes in patients with coronary artery disease and chronic heart failure?
This review highlights ivabradine as an effective heart-rate-lowering agent that improves cardiac outcomes in patients with stable coronary artery disease, stable angina, and left ventricular systolic dysfunction with elevated heart rates.
No takes yet. Share an insight, caveat, or question.
Supports ivabradine consideration in stable CAD with HR ≥70 bpm or angina; leaves open need for confirmatory RCTs.
Graziano Riccioni (2011) conducted a review in Coronary artery disease and chronic heart failure. Ivabradine vs. β-blockers and calcium channel antagonists was evaluated. Ivabradine improves cardiac outcomes in stable coronary artery disease and left ventricular systolic dysfunction in patients with heart rates ≥ 70 bpm and in patients with stable angina.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: